Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis

• Published in: European journal of cancer & clinical oncology Vol. 26; no. 6; pp. 691 - 694
• Main Authors: Kamthan, A.G., Lind, M.J., Thatcher, N., Steward, W.P., Hernandez Bronchud, M., Ranson, M.R., Stout, R.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 1990; New York, NY Pergamon Press
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Small Cell - drug therapy; Doxorubicin - administration & dosage; Etoposide - administration & dosage; Female; Humans; Ifosfamide - administration & dosage; Lung Neoplasms - drug therapy; Male; Medical sciences; Middle Aged; Neuropharmacology; Pharmacology. Drug treatments; Prognosis; Antineoplastic agent; Human; Chemotherapy; Prognosis; Treatment; Respiratory disease; Lung; Malignant tumor

61 patients with small cell lung cancer in a poor prognosis group were treated with chemotherapy and with thoracic radiotherapy if they had ‘limited stage’ disease. No prophylactic cranial irradiation was given. Chemotherapy comprised doxorubicin 50 mg/m 2 and ifosfamide 5 g/m 2 with mesna on day 1,...